Nexalin Technology (NASDAQ:NXL – Get Free Report) and Microbot Medical (NASDAQ:MBOT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
Institutional and Insider Ownership
0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 4.7% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Nexalin Technology has a beta of 4.08, meaning that its stock price is 308% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Nexalin Technology and Microbot Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
| Microbot Medical | 1 | 1 | 5 | 0 | 2.57 |
Microbot Medical has a consensus price target of $5.08, suggesting a potential upside of 439.80%. Given Microbot Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Microbot Medical is more favorable than Nexalin Technology.
Valuation & Earnings
This table compares Nexalin Technology and Microbot Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $300,000.00 | 4.16 | -$8.22 million | ($14.41) | -0.12 |
| Microbot Medical | N/A | N/A | -$13.14 million | ($0.24) | -3.92 |
Nexalin Technology has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nexalin Technology and Microbot Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
| Microbot Medical | N/A | -21.87% | -20.76% |
Summary
Microbot Medical beats Nexalin Technology on 8 of the 12 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
